|
The Cochrane Collaboration
Cochrane Reviews |
| Explore | New + Updated | Other languages |
|
 |
Vaccines for preventing plagueJefferson T, Demicheli V, Pratt M
Bookmark this:
     more ...
SummaryVaccines for preventing plaguePlain language summary pending.
This is a Cochrane review abstract and plain language summary, prepared and maintained by The Cochrane Collaboration, currently published in The Cochrane Database of Systematic Reviews 2010 Issue 1, Copyright © 2010 The Cochrane Collaboration. Published by John Wiley and Sons, Ltd.. The full text of the review is available in The Cochrane Library (ISSN 1464-780X).
This version first published online:
January 26. 1998 AbstractBackgroundPlague is endemic in China, Mongolia, Burma, Vietnam, Indonesia, India, large parts of Southern Africa, the United States and South America. There are three types of vaccines (live attenuated, killed and F1 fraction) with varying means of administration. ObjectivesThe objective of this review was to assess the effects of vaccines to prevent plague. Search strategyWe searched MEDLINE (1966 to February 2009), EMBASE (1985 to February 2009), CENTRAL (The Cochrane Library 2009, Issue 1) and reference lists of articles. We handsearched the journal 'Vaccine' (up to 1997) and contacted experts in the field. Selection criteriaRandomised trials comparing live and killed plague vaccines against no intervention, placebo, other plague vaccines or vaccines against other disease (control vaccines). Data collection and analysisThree reviewers assessed the eligibility of trials. Main resultsNo trials were included. Authors' conclusionsThere is not enough evidence to evaluate the effectiveness of any plague vaccine, or the relative effectiveness between vaccines and their tolerability. Circumstantial data from observational studies suggest that killed types may be more effective and have fewer adverse effects than attenuated types of vaccine. No evidence appears to exist on the long-term effects of any plague vaccine. |